Showing 1581-1590 of 2314 results for "".
- Stoke Therapeutics Presents New In-Vivo Data Demonstrating Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002https://modernod.com/news/stoke-therapeutics-presents-new-in-vivo-data-demonstrating-dose-related-target-engagement-and-opa1-protein-upregulation-in-retinal-tissue-following-administration-of-stk-002/2480831/Stoke Therapeutics announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002. Target engagement and OPA1 protein increases were sus
- Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucomahttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-published-in-journal-of-glaucoma/2480758/Nicox announced that the results from its Dolomites phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma. The publication “A R
- Penn Researchers Develop Gene Therapy that Restores Dim-Light Vision in Dogshttps://modernod.com/news/penn-researchers-develop-gene-therapy-that-restores-dim-light-vision-in-dogs/2480723/In the journal Proceedings of the National Academy of Sciences, University of Pennsylvania researchers reported a major advance: a gene therapy that returns night vision to dogs born with congenital stationary night blindness
- DORC Launches Eva Nexushttps://modernod.com/news/dorc-launches-eva-nexus/2480687/DORC International announced the launch of Eva Nexus, a device designed to improve efficiency and control in retina, cataract and combined surgery. Eva Nexus introduces multiple innovations in surgical performance and efficiency, including SmartIOP that combines with the existing E
- Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucomahttps://modernod.com/news/sight-sciences-launches-dont-wait-for-too-late-awareness-campaign-for-glaucoma/2480649/Sight Sciences announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma.
- Regeneron Presents Encouraging Phase 2 Results for High-Dose Aflibercept 8 mg in Wet AMDhttps://modernod.com/news/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-amd/2480636/Regeneron Pharmaceuticals announced results from its phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (AMD). The resul
- Dompé Announces First Patient Enrolled in Phase 3 Trial of Cenegermin in Patients With Severe Sjögren's-Related Dry Eye Diseasehttps://modernod.com/news/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2480630/Dompé announced that the first patient has been enrolled in its phase 3 clinical trial to evaluate the efficacy and safety of cenegermin in patients with severe Sjögren's-related dry eye disease, a primary symptom of Sjögren's. This trial is part of a program th
- DORC Announces Strategic Partnership With WEFIS for Research and Development of Ophthalmic Instrumentshttps://modernod.com/news/dorc-announces-strategic-partnership-with-wefis-for-research-and-development-of-ophthalmic-instruments/2480584/DORC International and WEFIS GmbH have announced a strategic partnership based on an equity investment by DORC. The partnership will focus on research and development aimed at improving performance, efficiency, and usability of cataract surgery instruments. Financial terms of the d
- AffaMed Therapeutics, licensee of Dextenza in Certain Asian Markets, Doses Their First Patient in Clinical Trial in Cataract Surgery Patientshttps://modernod.com/news/affamed-therapeutics-licensee-of-dextenza-in-certain-asian-markets-doses-their-first-patient-in-clinical-trial-in-cataract-surgery-patients/2480574/Ocular Therapeutix announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain post-cataract surger
- Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Nonclinical Developmenthttps://modernod.com/news/nicox-appoints-doug-hubatsch-as-new-chief-scientific-officer-to-lead-clinical-and-nonclinical-development/2480509/Nicox SA announced the appointment of Doug Hubatsch to lead all of the company’s nonclinical and clinical development activities. As Chief Scientific Officer, Mr. Hubatsch will be responsible for setting the research and development st